RECOGNITION AT EUROPEAN INNOVATION COUNCIL’S INVESTOR DAY

November 30, 2022

We are delighted to announce that Dr. Niv Bachnoff, our Chief Scientific Officer, has won the First Prize for Best Presentation in the Biotech & Pharmaceuticals category at the European Innovation Council’s Investor Day on Healthcare, which took place in Lisbon in November, presenting Omnix Medical to Investors and fellow EIC H2020 champions and raising awareness for the fight against AMR.

Omnix Medical is a clinical-stage biopharmaceutical company focused on developing innovative anti-infective drugs to combat the growing problem of Antimicrobial Resistance (AMR). Our goal is to offer safer and more effective treatments that are less prone to resistance, to effectively address the threat posed by AMR. We are dedicated to finding a solution to this pressing issue and are confident that our therapies will make a significant impact in the fight against AMR.

More To Explore

A Phase I First-in-Human Study To Evaluate the Safety and Pharmacokinetic (PK) Properties of the Intravenously (IV) Administered OMN6

A Phase I First-in-Human Study To Evaluate the Safety and Pharmacokinetic (PK) Properties of the Intravenously (IV) Administered OMN6, a Novel Antimicrobial Peptide Targeting Acinetobacter

Safety and Pharmacokinetic Results from the First-in-Human Study with Intravenously Administered OMN6 (A Poster)

Safety and Pharmacokinetic Results from the First-in-Human Study with Intravenously Administered OMN6, a Novel Antimicrobial Peptide for Acinetobacter baumannii (AB), Conducted in Healthy Volunteers Access

Omnix Medical Granted Fast-Track Designation by U.S. FDA for its Next-Generation Anti-Infective OMN6

Designation underlines the need for novel, first-in-class antimicrobials for the treatment of infections with Gram-negative bacteria Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for

Contact Us

Reach US

A-2-Z - Digital Accessibility and Marketing

Omnix Medical Ltd. is committed to making its website and all its electronic information easier to use and more accessible for people with disabilities. The company’s website was created and/or updated according to the provisions of the Equal Rights for People with Disabilities Law, 5748-1998, and the delegated legislation stemming from it, and it fully complies with the W3C Web Content Accessibility Guidelines 2.0, AA level.

Omnix Medical Ltd. will continue its efforts to constantly improve the accessibility of its website and information in the belief that it is our collective moral obligation to allow seamless, accessible, and unhindered use also for those of us with disabilities.

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under Grant Agreement No 966627 (OMNIX MEDICAL).